NOVARTIND2,420.80

Novartis India Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLPARNAXLABSGRLSHUKRAPHARSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Revenue from Operations378.7335.1356.3
Other Income58.161.742.0
Total Income436.9396.8398.2
Expenses
+ Purchases of Stock-in-Trade199.3
+ Changes in Inventories2.49.93.8
+ Employee Benefit Expense35.623.018.7
+ Finance Costs1.81.50.8
+ Depreciation & Amortisation6.12.62.2
+ Other Expenses76.046.843.5
Total Expenses321.5273.9267.8
EBITDA65.165.391.4
EBIT59.062.789.2
Profit
PBT before Exceptional Items115.4
Pretax Income115.4122.8130.4
+ Current Tax1.737.630.0
+ Deferred Tax10.30.0-0.4
Tax Expense12.037.729.5
Net Income103.485.2100.9
+ Other Comprehensive Income3.11.21.0
Total Comprehensive Income106.586.4101.9
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit177.1
Gross Margin %46.75
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)115.4
Net Income Adj (tax-effected)103.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.